Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Update on PSA testing.

Mark L Gonzalgo1, H Ballentine Carter

  • 1Department of Urology, Phipps 560-A, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA. gonzalgo@jhmi.edu

Journal of the National Comprehensive Cancer Network : JNCCN
|August 19, 2007
PubMed
Summary

Prostate-specific antigen (PSA) testing for prostate cancer screening presents challenges in interpretation and optimal use. Ongoing trials aim to confirm screening effectiveness and cost-effective strategies for reducing prostate cancer deaths.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease.

The Journal of urology·2026
Same author

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same author

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Journal of endourology·2026
Same author

Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.

Urology practice·2026
Same author

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.

Cancer research·2026
Same author

Development and validation of a machine learning model for predicting 30-day major morbidity and mortality following radical cystectomy: An American College of Surgeons National Surgical Quality Improvement Program study.

BJUI compass·2026

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate-specific antigen (PSA) testing has seen a significant rise in prostate cancer screening over the last decade.
  • Interpreting total PSA levels and monitoring changes over time remain complex challenges in clinical practice.
  • Established guidelines for early prostate cancer detection are crucial for minimizing unnecessary testing and optimizing screening approaches.

Purpose of the Study:

  • To discuss the optimal utilization and interpretation of PSA testing in prostate cancer screening.
  • To review current considerations for PSA screening, including initiation age, testing intervals, and PSA value fluctuations.
  • To contextualize these discussions within recent scientific discoveries and ongoing research.

Main Methods:

  • Review of current literature and guidelines regarding PSA testing for prostate cancer.
  • Discussion of factors influencing PSA levels, such as age, testing frequency, and biological variability.
  • Consideration of data from ongoing randomized controlled trials on prostate cancer screening.

Main Results:

  • The interpretation of PSA levels and their changes over time requires careful consideration of individual patient factors and established guidelines.
  • Determining the optimal age to initiate screening and appropriate testing intervals are key areas of ongoing research.
  • Current research highlights the importance of understanding PSA dynamics for effective screening.

Conclusions:

  • Efficient use of PSA testing and clear interpretation guidelines are essential for successful prostate cancer screening.
  • Further results from randomized trials are anticipated to clarify the effectiveness and cost-efficiency of PSA screening in reducing mortality.
  • Evidence-based strategies are needed to balance the benefits of early detection with the risks of overdiagnosis and overtreatment.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 13, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025